Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone vs placebo in post-COVID-19 pulmonary fibrosis (Phase II)
2020-002518-42Phase 2Active
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis (PF) and Post-COVID-19 lung disease (PCLD) comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Clinical success rate (functional and radiologic improvement at 6 months). Started Oct 2020; status: active.
02
Drugs
pirfenidone
03
Conditions
pulmonary fibrosis (PF)Post-COVID-19 lung disease (PCLD)
Beyond the preview
Go deeper on 2020-002518-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002518-42.